The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
Open accessAbstract
PURPOSE: To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer. PATIENTS AND METHODS: Nine hundred seven patients were randomly assigned letrozole 2.5 mg once daily (453 patients) or tamoxifen 20 mg once daily (454 patients). Patients had estrogen receptor– and/or progesterone receptor–positive tumors, or both receptors were unknown. Recurrence during adjuvant antiestrogen therapy or within the following 12 months or prior endocrine therapy for advanced disease precluded enrollment. One prior chemotherapy regimen for metastatic disease was allowed. The primary end point was time to progression (TTP). Secondary end points included overall objective response rate (ORR), its duration, rate and duration of clinical benefit, time to treatment failure (TTF), overall survival, and tolerability. RESULTS: TTP was significantly longer for letrozole than for tamoxifen (median, 41 v 26 weeks). Treatment with letrozole reduced the risk of progression by 30% (hazards ratio, 0.70; 95% confidence interval, 0.60 to 0.82, P = .0001). TTP was significantly longer for letrozole irrespective of dominant site of disease, receptor status, or prior adjuvant antiestrogen therapy. Similarly, TTF was significantly longer for letrozole (median, 40 v 25 weeks). ORR was higher for letrozole (30% v 20%; P = .0006), as was the rate of clinical benefit (49% v 38%; P = .001). Survival data are currently immature and not reported here. Both treatments were well tolerated. CONCLUSION: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate. Our results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 259
Self-citationHamilton, A. L., & Piccart, M. J. (1999) · Annals of Oncology · doi:10.1023/a:1008368300827 · Cited by 118
Tamoxifen in the Treatment of Breast Cancer
Legha, S. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-3-219 · Cited by 111
Dowsett, M., Pfister, C. U., Johnston, S. R. D., Miles, D. W., Houston, S. J., Verbeek, J. A., Gundacker, H. M., Sioufi, A., & Smith, I. E. (1999) · PubMed · Cited by 90
Self-citationLü, Q., Liu, Y., Long, B. J., Grigoryev, D. N., Gimbel, M. I., & Brodie, A. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006225601046 · Cited by 86
Muss, H. B., Wells, H. B., Paschold, E., Black, W. R., Cooper, M. R., Capizzi, R. L., Christian, R., Cruz, J. M., Jackson, D. V., & Powell, B. L. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1098 · Cited by 77
Aromatase inhibitors and their antitumor effects in model systems.
Brodie, A., Lü, Q., Liu, Y., & Long, B. J. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060205 · Cited by 75
The effects of aromatase inhibitors and antiestrogens in the nude mouse model
Lü, Q., Yue, W., Wang, J., Liu, Y., Long, B. J., & Brodie, A. M. H. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006004930930 · Cited by 72
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity
Long, B. J., Tilghman, S. L., Yue, W., Thiantanawat, A., Grigoryev, D. N., & Brodie, A. M. H. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00122-8 · Cited by 71
Muss, H. B., Case, L. D., Atkins, J., Bearden, J. D., Cooper, M. R., Cruz, J. M., Jackson, D. V., O’Rourke, M. A., Pavy, M. D., & Powell, B. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1630 · Cited by 70
Gill, P. G., Gebski, V., Snyder, R. D., Burns, I., Levi, J. A., Byrne, M., & Coates, A. S. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058658 · Cited by 44
Self-citationIngle, J. N., Twito, D. I., Schaid, D. J., Cullinan, S. A., Krook, J. E., Mailliard, J. A., Marschke, R. F., Long, H. J., Gerstner, J. G., & Windschitl, H. E. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.5.825 · Cited by 30
Cited by
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Sources of estrogen and their importance
Simpson, E. R. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00360-1 · Cited by 936
Metadata
- Authors
- Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P. P., Salminen, E., Snyder, R., Lassus, M., Verbeek, J. A., Staffler, B., Chaudri-Ross, H. A., & Dugan, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-05-15
- Volume
- 19
- Issue
- 10
- Pages
- 2596-2606
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1918073772
- Cited by
- 1,015
- References
- 17
- FWCI
- 36.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.